• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices.聚-ADP核糖聚合酶抑制剂时代的复发性卵巢癌：是时候重新评估既定临床实践了。
ESMO Open. 2021 Jun;6(3):100135. doi: 10.1016/j.esmoop.2021.100135. Epub 2021 Apr 27.
2
An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.上皮性卵巢癌的当前及新出现疗法的最新进展：聚焦于聚（二磷酸腺苷 - 核糖）聚合酶抑制和抗血管生成。
J Oncol Pharm Pract. 2017 Sep;23(6):454-469. doi: 10.1177/1078155216657165. Epub 2016 Jun 29.
3
Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.聚-ADP-核糖聚合酶（PARP）抑制剂与卵巢功能。
Biomed Pharmacother. 2023 Jan;157:114028. doi: 10.1016/j.biopha.2022.114028. Epub 2022 Nov 18.
4
U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.美国食品和药物管理局批准的聚（ADP-核糖）聚合酶抑制剂维持治疗复发性卵巢癌：成本效益分析。
Obstet Gynecol. 2019 Apr;133(4):795-802. doi: 10.1097/AOG.0000000000003171.
5
Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.尼拉帕利治疗复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌。
Ann Pharmacother. 2020 Oct;54(10):1010-1015. doi: 10.1177/1060028020912749. Epub 2020 Mar 16.
6
Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.聚（腺苷二磷酸核糖）聚合酶（PARP）抑制剂作为新诊断卵巢癌女性的维持治疗：系统评价和荟萃分析。
Arch Gynecol Obstet. 2021 Aug;304(2):285-296. doi: 10.1007/s00404-021-06070-2. Epub 2021 May 21.
7
PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials.聚（ADP - 核糖）聚合酶（PARP）抑制剂用于铂敏感复发性卵巢癌：一项随机对照试验的荟萃分析
Oncol Res Treat. 2018;41(4):226-235. doi: 10.1159/000486418. Epub 2018 Mar 23.
8
Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with mutational status: a systematic review and network meta-analysis.比较聚（ADP-核糖）聚合酶抑制剂（PARPi）作为新诊断和铂敏感复发性卵巢癌与突变状态的维持治疗：系统评价和网络荟萃分析。
Expert Rev Anticancer Ther. 2024 Jan-Feb;24(1-2):59-69. doi: 10.1080/14737140.2023.2298832. Epub 2024 Feb 12.
9
Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer.聚（ADP - 核糖）聚合酶（PARP）抑制剂与卵巢癌
Taiwan J Obstet Gynecol. 2017 Oct;56(5):713-714. doi: 10.1016/j.tjog.2017.08.026.
10
Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer.聚（ADP - 核糖）聚合酶（PARP）抑制剂用于晚期卵巢癌一线及二线化疗缓解后的维持治疗的成本效益
J Oncol Pharm Pract. 2023 Mar;29(2):457-464. doi: 10.1177/10781552221137705. Epub 2022 Nov 7.

引用本文的文献

1
Prognostic Role of CA-125 Elimination Rate Constant (KELIM) in Patients with Advanced Epithelial Ovarian Cancer Who Received PARP Inhibitors.CA-125清除率常数（KELIM）在接受PARP抑制剂治疗的晚期上皮性卵巢癌患者中的预后作用
Cancers (Basel). 2024 Jun 26;16(13):2339. doi: 10.3390/cancers16132339.
2
A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy.上皮性卵巢癌患者在接受多聚 ADP-核糖聚合酶抑制剂维持治疗后疾病进展时的治疗模式的真实世界研究。
J Ovarian Res. 2024 Mar 5;17(1):55. doi: 10.1186/s13048-024-01381-9.
3
Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022.2013年至2022年卵巢癌耐药性的文献计量学与可视化分析
Front Oncol. 2023 May 18;13:1173863. doi: 10.3389/fonc.2023.1173863. eCollection 2023.
4
Ovarian cancer recurrence: "is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?".卵巢癌复发：“铂耐药的定义是否会因PARP抑制剂和其他干预治疗而改变？”
Cancer Drug Resist. 2022 Jun 1;5(2):451-458. doi: 10.20517/cdr.2021.138. eCollection 2022.
5
Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma.聚（ADP-核糖）聚合酶抑制剂联合贝伐单抗对铂耐药复发性卵巢上皮癌的影响
Comput Math Methods Med. 2022 Jun 10;2022:4600145. doi: 10.1155/2022/4600145. eCollection 2022.

本文引用的文献

1
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.奥拉帕利维持治疗后进展的 BRCA1/2 突变复发性上皮性卵巢癌患者后续化疗的疗效：SOLO2/ENGOT Ov-21 试验的事后分析。
Ann Oncol. 2022 Oct;33(10):1021-1028. doi: 10.1016/j.annonc.2022.06.011. Epub 2022 Jun 27.
2
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.铂敏感复发性卵巢癌中二次细胞减灭术加化疗与单纯化疗的比较（SOC-1）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2021 Apr;22(4):439-449. doi: 10.1016/S1470-2045(21)00006-1. Epub 2021 Mar 8.
3
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.卡铂为基础的双联化疗加贝伐珠单抗治疗铂敏感型卵巢癌患者的疗效优于卡铂为基础的双联化疗单药治疗：一项随机、3 期临床试验。
Lancet Oncol. 2021 Feb;22(2):267-276. doi: 10.1016/S1470-2045(20)30637-9.
4
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer.克服卵巢癌中的铂类和PARP抑制剂耐药性
Cancers (Basel). 2020 Jun 17;12(6):1607. doi: 10.3390/cancers12061607.
5
PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair.聚腺苷二磷酸核糖聚合酶抑制剂在卵巢癌中的应用：目前的适应证、未来的联合用药策略，以及针对 DNA 损伤修复的新型研发药物
Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-16. doi: 10.1200/EDBK_288015.
6
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.奥拉帕利联合贝伐珠单抗作为卵巢癌一线维持治疗。
N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.
7
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.奥拉帕利作为 BRCA1-2 突变的复发性铂类敏感卵巢癌患者的维持治疗：真实世界数据和进展后结局。
Gynecol Oncol. 2020 Jan;156(1):38-44. doi: 10.1016/j.ygyno.2019.10.023. Epub 2019 Nov 4.
8
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.尼拉帕利治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.
9
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.奥拉帕利维持治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.
10
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.芦卡帕利维持治疗铂类化疗后缓解的复发性卵巢癌（ARIEL3）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12.

Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices.

作者信息

Bartoletti M, Cecere S C, Musacchio L, Sorio R, Puglisi F, Pignata S

机构信息

Department of Medicine (DAME), University of Udine, Udine, Italy; Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), Aviano (PN), Italy.

Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.

出版信息

ESMO Open. 2021 Jun;6(3):100135. doi: 10.1016/j.esmoop.2021.100135. Epub 2021 Apr 27.

DOI:10.1016/j.esmoop.2021.100135
PMID:33930658
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8100608/
Abstract
摘要